var data={"title":"Hydroxyzine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Hydroxyzine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6346?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">see &quot;Hydroxyzine: Drug information&quot;</a> and <a href=\"topic.htm?path=hydroxyzine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Hydroxyzine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181115\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vistaril</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181116\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Hydroxyzine;</li>\n      <li>Atarax;</li>\n      <li>Hydroxyzine Hydrochloride Injection, USP;</li>\n      <li>Novo-Hydroxyzin;</li>\n      <li>PMS-Hydroxyzine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053308\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antianxiety Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antihistamine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sedative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053301\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">see &quot;Hydroxyzine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infants, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Antiemetic:</b> IM: 1.1 mg/kg/dose; maximum single dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Anxiety:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &lt;6 years: 50 mg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents &ge;6 years: 50-100 mg/day in 4 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral: Children and Adolescents: 2 mg/kg/day divided every 6-8 hours as needed; <b>Note:</b> Some experts have recommended lower initial doses. Maximum single dose is age-dependent: Age &lt;6 years: 12.5 mg; age 6-12 years: 25 mg; age &gt;12 years: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM: Children and Adolescents: 0.5-1 mg/kg/<b>dose</b> every 4-6 hours as needed; maximum single dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pruritus; associated with allergic conditions or chronic urticaria:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children &lt;6 years: 50 mg/day in 4 divided doses as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Children and Adolescents &ge;6 years: 50-100 mg/day in 4 divided doses as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: Children and Adolescents: Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Patient weight &le;40 kg: 2 mg/kg/day divided every 6-8 hours as needed (Simons, 1994); <b>Note:</b> Some experts have recommended lower doses; maximum single dose: 25 mg </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Patient weight &gt;40 kg: 25-50 mg once daily at bedtime or twice daily (Simons, 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b> Pruritus; associated with opioid use:</b> Children and Adolescents: Limited data available: IM, Oral: 0.5 mg/kg/dose every 6 hours as needed; maximum single dose: 50 mg (Berde, 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Sedation; procedural, pre-/postoperative:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Manufacturer's labeling: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Oral: Children and Adolescents: 0.6 mg/kg/<b>dose</b>; maximum single dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">IM: Infants, Children, and Adolescents: 1.1 mg/kg/<b>dose</b>; maximum single dose: 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Alternate dosing: Oral: Children 2-5 years: 1 mg/kg/<b>dose</b> as a single dose 30-45 minutes prior to procedure in combination with other sedatives (eg, midazolam, chloral hydrate) has been used in preschool children prior to dental procedures or echocardiograms (Chowdhury, 2005; Roach, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Antiemetic:</b> IM: 25-100 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Anxiety:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 50-100 mg 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 50&ndash;100 mg every 4-6 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Preoperative sedation: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 50-100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: 25-100 mg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pruritus:</b> Oral: 25 mg 3-4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Psychiatric emergency:</b> IM: 50-100 mg immediately; repeat every 4-6 hours as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; active metabolite (cetirizine) is renally eliminated (Simons, 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: In patients with primary biliary cirrhosis, change dosing interval to every 24 hours (Simons, 1989)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181090\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral, as pamoate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vistaril: 25 mg, 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intramuscular, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg/mL (1 mL [DSC]); 50 mg/mL (1 mL [DSC], 2 mL [DSC], 10 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (473 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg/5 mL (25 mL, 118 mL, 473 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 25 mg, 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181075\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053312\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: May be administered without regard to food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: Subcutaneous, intra-arterial, and IV administration are contraindicated and <b>not</b> recommended under any circumstances; intravascular hemolysis, thrombosis, and digital gangrene can occur; extravasation can result in sterile abscess and marked tissue induration. Administer IM deep in large muscle. For IM administration in children, injections should be made into the midlateral muscles of the thigh. In the very rare instance that IV administration may be necessary, slow IV injection through a central venous line has been used in pediatric oncology patients (Berde, 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vesicant; the manufacturer considers IV administration a contraindication; however, if IV administration is necessary ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181110\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect oral solution from light; do not freeze.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053311\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Treatment of anxiety and pruritus; preoperative sedation [FDA approved in pediatric patients (age not specified) and adults] </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Treatment of anxiety and pruritus; perioperative sedation; antiemetic [FDA approved in infants, children, adolescents, and adults] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181169\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">HydrOXYzine may be confused with hydrALAZINE, hydroxyurea</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Atarax may be confused with Ativan</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vistaril may be confused with Restoril, Versed, Zestril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Hydroxyzine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Hydroxyzine, as a single agent or as part of a combination, is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Vistaril [US and Turkey] may be confused with Vastarel brand name for trimetazidine [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181166\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness (transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Respiratory depression (high doses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute generalized exanthematous pustulosis, fixed drug eruption, hallucination, headache, hypersensitivity reaction, involuntary movements, prolonged Q-T interval on ECG, pruritus, seizure (high doses), skin rash, torsades de pointes, tremor (high doses), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181097\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to hydroxyzine or any component of the formulation; early pregnancy; prolonged QT interval</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Hypersensitivity to cetirizine or levocetirizine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: SubQ, intra-arterial, or IV administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Oral: Hypersensitivity to other piperazine derivatives, aminophylline or ethylenediamine; history of history of cardiac arrhythmias; significant electrolyte imbalance (eg, hypokalemia, hypomagnesemia); significant bradycardia; family history of sudden cardiac death; concomitant use with other QT interval prolonging drugs or with CYP3A4/5 inhibitors; asthmatics who have previously experienced a serious anti-histamine induced adverse bronchopulmonary effect; porphyria.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181079\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute generalized exanthematous pustulosis: May rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction involving fever, pustules and large areas of edematous erythema. Discontinue at first sign of skin rash, worsening of pre-existing skin reactions or any other sign of hypersensitivity; if signs or symptoms suggest AGEP, do not resume therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation/torsades de pointes: Has been reported, with the majority occurring in patients with other risk factors for QT prolongation/torsades de pointes (eg, preexisting cardiac disease, electrolyte imbalances, concomitant arrhythmogenic use). Use with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias. Oral hydroxyzine is contraindicated in patients with a prolonged QT interval.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Elderly: May cause over sedation in the elderly; initiate elderly patients on low does and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).   See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: Parenteral: For IM use only. Severe injection-site reactions have been reported with IM administration (eg, extensive tissue damage, necrosis, gangrene) requiring surgical intervention (including debridement, skin grafting, and amputation). SubQ, IV, and intra-arterial routes of administration are contraindicated. Intravascular hemolysis, thrombosis, and digital gangrene have been reported with IV or intra-arterial administration (Baumgartner 1979); SubQ administration may result in significant tissue damage. If <b>inadvertent</b> IV administration results in extravasation, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Long-term use: The effectiveness of hydroxyzine for long-term use (&gt;4 months) has not been assessed; periodically reassess use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26022640\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neonatal withdrawal symptoms, including seizures, have been reported following long-term maternal use or the use of large doses near term (Serreau, 2005). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181155\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181084\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13368&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the sedative effect of Antihistamines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: HydrOXYzine may enhance the CNS depressant effect of Barbiturates.  Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: HydrOXYzine may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of HydrOXYzine. Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of HydrOXYzine. Management: This combination is specifically contraindicated in some non-U.S. labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meperidine: HydrOXYzine may enhance the CNS depressant effect of Meperidine.  Management: Consider a decrease in meperidine dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181101\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Use of hydroxyzine early in pregnancy is contraindicated.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Adverse events were observed in animal reproduction studies. Hydroxyzine crosses the placenta. Possible withdrawal symptoms have been observed in neonates following chronic maternal use of hydroxyzine during pregnancy (Prenner 1977; Serreau 2005).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Hydroxyzine is approved for pre- and postpartum adjunctive therapy to reduce opioid dosage, treat anxiety, and control emesis. Hydroxyzine may be used as an antipruritic if systemic therapy is needed in pregnant women (use caution late in pregnancy) (Murase 2014); although other agents may be preferred (Powell 2015; Zuberbier 2014). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy (Ambros-Rudolph 2011; Kremer 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1053307\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Relief of symptoms, mental status, blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181078\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract (Simons 1994). Possesses skeletal muscle relaxing, bronchodilator, antihistamine, antiemetic, and analgesic properties.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181096\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: 15 to 30 minutes; IM: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Decreased histamine-induced wheal and flare areas: 2 to &ge;36 hours; Suppression of pruritus: 1 to 12 hours (Simon F 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Children and Adolescents 1 to 14 years: 18.5 &plusmn; 8.6 L/kg (Simons F 1984a); Adults: V<sub>d</sub>: 16 &plusmn; 3 L/kg (Simons F 1984); Elderly: ~23 L/kg (Simons K 1989); Hepatic dysfunction: ~23 L/kg (Simons F 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to multiple metabolites, including cetirizine (active) (Simons F 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 1 to 14 years (mean age: 6.1 &plusmn; 4.6 years): 7.1 &plusmn; 2.3 hours; <b>Note: </b>Half-life increased with increasing age and was 4 hours in patients 1 year of age and 11 hours in a 14-year-old patient (Simons F 1984a) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~20 hours (Simons 1984); Elderly: ~29 hours (Simons K 1989); Hepatic dysfunction: ~37 hours (Simons F 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral administration: Serum: ~2 hours; Peak suppression of antihistamine-induced wheal and flare: 4 to 12 hours (Simons F 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine; active metabolite (cetirizine) is renally eliminated (Simons F 1994) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181100\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (HydrOXYzine Pamoate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $29.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $32.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $119.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Vistaril Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $294.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $359.62</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (HydrOXYzine HCl Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (1 mL): $24.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/mL (1 mL): $26.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (HydrOXYzine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (473 mL): $39.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (HydrOXYzine HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $62.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $91.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $111.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181102\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arax (TW);</li>\n      <li>Artica (BD);</li>\n      <li>Ataraks (UA);</li>\n      <li>Atarax (AE, AT, AU, BB, BE, BG, BH, BM, BS, BZ, CH, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HU, IN, IS, IT, JM, JO, KW, LB, LK, LU, MT, MX, MY, NI, NL, NO, PA, PE, PL, PT, QA, RU, SA, SE, SI, SK, SR, SV, TH, TR, TT, TW, VN);</li>\n      <li>Atarax Uce (PK);</li>\n      <li>Ataraxone (AR, UY);</li>\n      <li>Aterax (ZA);</li>\n      <li>Bestalin (ID);</li>\n      <li>Calmofilase (CO);</li>\n      <li>Cedar (CO);</li>\n      <li>Centilax (KR);</li>\n      <li>Disron-P (JP);</li>\n      <li>Dormirex (GT);</li>\n      <li>Evazine (PH);</li>\n      <li>Fedox (PY);</li>\n      <li>Hadarax (TH);</li>\n      <li>Hiderax (CO);</li>\n      <li>Hidroxina (EC);</li>\n      <li>Histan (TH);</li>\n      <li>Histarax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Hizin (SG, TH);</li>\n      <li>Hydarax (VN);</li>\n      <li>Hytis (BD);</li>\n      <li>Iremofar (GR);</li>\n      <li>Iterax (ID, PH);</li>\n      <li>Nexit (CL);</li>\n      <li>Nirax (TW);</li>\n      <li>Otarex (IL);</li>\n      <li>Paxistil (BE);</li>\n      <li>Polizine (TH);</li>\n      <li>Prurid (PY);</li>\n      <li>Qualidrozine (HK);</li>\n      <li>Roxyzin (BD);</li>\n      <li>Sedazine (PH);</li>\n      <li>Serecid (NZ);</li>\n      <li>Ucerax (IE, KR);</li>\n      <li>Vistaril (KE, SE, TR, TW);</li>\n      <li>Warazix (JP);</li>\n      <li>Xyril (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ambros-Rudolph CM. Dermatoses of pregnancy - clues to diagnosis, fetal risk and therapy. <i>Ann Dermatol</i>. 2011;23(3):265-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/21909194/pubmed\" target=\"_blank\" id=\"21909194\">21909194</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baumgartner TG, &quot;Administration of Hydroxyzine Injection,&quot; <i>Am J Hosp Pharm</i>, 1979, 36(12):1660.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/525641/pubmed\" target=\"_blank\" id=\"525641\">525641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berde C, Ablin A, Glazer J, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):818-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2216644/pubmed\" target=\"_blank\" id=\"2216644\">2216644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24528912/pubmed\" target=\"_blank\" id=\"24528912\">24528912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chowdhury J and Vargas KG, &quot;Comparison of Chloral Hydrate, Meperidine, and Hydroxyzine to Midazolam Regimens for Oral Sedation of Pediatric Dental Patients,&quot; <i>Pediatr Dent</i>, 2005, 27(3):191-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/16173222/pubmed\" target=\"_blank\" id=\"16173222\">16173222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. <i>Clin Res Hepatol Gastroenterol</i>. 2011;35(2):89-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/21809485/pubmed\" target=\"_blank\" id=\"21809485\">21809485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/3928731/pubmed\" target=\"_blank\" id=\"3928731\">3928731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24528911/pubmed\" target=\"_blank\" id=\"24528911\">24528911</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema.<i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25711134/pubmed\" target=\"_blank\" id=\"25711134\">25711134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prenner BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. <i>Am J Dis Child</i>. 1977;131(5):529-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/855838/pubmed\" target=\"_blank\" id=\"855838\">855838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roach CL, Husain N, Zabinsky J, et al, &quot;Moderate Sedation for Echocardiography of Preschoolers,&quot; <i>Pediatr Cardiol</i>, 2010, 31(4):469-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/20047024/pubmed\" target=\"_blank\" id=\"20047024\">20047024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serreau R, Komiha M, Blanc F, et al, &quot;Neonatal Seizures Associated With Maternal Hydroxyzine Hydrochloride in Late Pregnancy,&quot; <i>Reprod Toxicol</i>, 2005, 20(4):573-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/16199350/pubmed\" target=\"_blank\" id=\"16199350\">16199350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE and Simons KJ, &quot;The Pharmacology and Use of H1-Receptor-Antagonist Drugs,&quot; <i>N Engl J Med</i>, 1994, 330(23):1663-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/7909915/pubmed\" target=\"_blank\" id=\"7909915\">7909915</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Simons KJ, and Frith EM, &quot;The Pharmacokinetics and Antihistaminic of the H<sub>1</sub> Receptor Antagonist Hydroxyzine,&quot; <i>J Allergy Clin Immunol</i>, 1984a, 73(1 Pt 1):69-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6141198/pubmed\" target=\"_blank\" id=\"6141198\">6141198</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Simons KJ, Becker AB, et al, &quot;Pharmacokinetics and Antipruritic Effects of Hydroxyzine in Children With Atopic Dermatitis,&quot; <i>J Pediatr</i>, 1984, 104(1):123-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6361228/pubmed\" target=\"_blank\" id=\"6361228\">6361228</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simons FE, Watson WT, Chen XY, et al, &quot;The Pharmacokinetics and Pharmacodynamics of Hydroxyzine in Patients With Primary Biliary Cirrhosis,&quot; <i>J Clin Pharmacol</i>, 1989, 29(9):809-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2572611/pubmed\" target=\"_blank\" id=\"2572611\">2572611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: adescriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25183382/pubmed\" target=\"_blank\" id=\"25183382\">25183382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong AR and Rasool AH, &quot;Hydroxyzine-Induced Supraventricular Tachycardia in a Nine-Year-Old Child,&quot; <i>Singapore Med J</i>, 2004, 45(2):90-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/14985850/pubmed\" target=\"_blank\" id=\"14985850\">14985850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy</i>. 2014;69(7):868-887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24785199/pubmed\" target=\"_blank\" id=\"24785199\">24785199</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13368 Version 242.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181115\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181116\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1053308\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1053301\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181090\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F181075\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1053312\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F181110\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1053311\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181169\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181166\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181097\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181079\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26022640\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F181155\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181084\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F181101\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1053307\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181078\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F181096\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F181100\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181102\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13368|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">Hydroxyzine: Drug information</a></li><li><a href=\"topic.htm?path=hydroxyzine-patient-drug-information\" class=\"drug drug_patient\">Hydroxyzine: Patient drug information</a></li></ul></div></div>","javascript":null}